Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion

@article{Oki2006AdvantagesFT,
  title={Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion},
  author={Tomomi Oki and Ayako Toma-Okura and Shizuo Yamada},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2006},
  volume={316},
  pages={1137 - 1145}
}
To clarify pharmacological usefulness of transdermal oxybutynin in the therapy of overactive bladder, we have characterized muscarinic receptor binding in rat tissues with measurement of plasma concentrations of oxybutynin and its metabolite N-desethyl-oxybutynin (DEOB) and salivation after transdermal oxybutynin compared with oral route. At 1 and 3 h after oral administration of oxybutynin, there was a significant increase in apparent dissociation constant (Kd) for specific [N-methyl-3H… 

Figures and Tables from this paper

Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder

TLDR
It is demonstrated that imidafenacin administered orally distributes predominantly to the bladder and exerts more selective and longer-lasting effect on the bladder than other tissues, such as the submaxillary gland, colon, and brain.

Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate.

TLDR
The present study provides the first evidence that tiotropium, ipratopium, and glycopyrrolate administered intratracheally in rats selectively bound muscarinic receptors of the lung, and tiotroropium and Glycopyrroate had a much longer-lasting effect than ipratropium.

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding

TLDR
In vivo quantitative autoradiography with (+)N-[11C]methyl-3-piperidyl benzilate in rats shows significant occupancy of brain muscarinic receptors with the intravenous injection of oxybutynin, solifenacin, and tolterodine, suggesting preferentialMuscarinic receptor binding in the bladder.

Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.

TLDR
The present study indicates that the weak suppression of cholinergic salivation by solifenacin compared with oxybutynin may be partially attributed to its relatively fast dissociation kinetics from exocrine muscarinic receptors.

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder

TLDR
OTG represents an efficacious, safe, and convenient alternative to other oxybutynin formulations and other oral anticholinergic medications for the treatment of OAB and should be confirmed by broad clinical experience.

The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.

TLDR
In vivo quantitative autoradiography using (+)N-[(11)C]methyl-3-piperidyl benzilate in rats showed significant occupancy of brain muscarinic receptors on intravenous injection of oxybutynin, propiverine, solifenacin, and tolterodine, and the newer generation of antimuscarinic agents may be advantageous in the bladder selectivity after systemic administration.

Transdermal Oxybutynin

TLDR
Health-related quality-of-life improvements with transdermal oxybutynin were shown in patients with overactive bladder in the open-label MATRIX trial, as demonstrated by significant improvements in all domains of the King’s Health Questionnaire.

Synthesis of 99mTc-oxybutynin for M3-receptor-mediated imaging of urinary bladder

TLDR
This study aimed to optimize radiolabeling yield of oxybutynin with 99mTc using SnCl2·2H2O as a reducing agent with respect to factors that affect the reaction conditions such as oxy butynin amount, stannous chloride amount, reaction time and pH of the reaction mixture.

Inhibition of salivary secretion by tolterodine transdermal patch

TLDR
It is suggested that tolterodine transdermal patch could be a useful formulation that provides uniform and consistent inhibitory effects to effectively control OAB symptoms with reduced severity of dry mouth in comparison to the oral formulation.

References

SHOWING 1-10 OF 50 REFERENCES

Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.

TLDR
Intravesical oxybutynin in rats may cause selective binding of bladder muscarinic receptors via a direct local effect, while oral oxy butynin may exert predominant binding of salivary gland receptors.

COMPARISON OF OXYBUTYNIN AND ITS ACTIVE METABOLITE, PAROTID GLAND N-DESETHYL-OXYBUTYNIN, IN THE HUMAN DETRUSOR AND

TLDR
It is concluded that oxybutynin and N-desethyl-oxy butynin have a similar antimuscarinic effect in the human detrusor, and the same binding characteristics indetrusor and parotid gland, respectively.

M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland

TLDR
M3 receptor antagonism by solifenacin could be bladder-selective and may provide new approaches to the pharmacotherapy of overactive bladder, as well as study the tissue selectivity between bladders and salivary glands.

Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration.

Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.

Muscarinic receptor binding in the parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum.

Some properties of the muscarinic receptors in guinea pig parotid gland were studied by receptor binding, using 1-Quinuclidinyl [phenyl 4-3H] benzilate ((-)3H-QNB) as radio-ligand. In equilibrium

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.

TLDR
Lower N-desethyloxybutynin plasma concentration and greater saliva output during transdermal treatment correspond to the reported low incidence of dry mouth in patients with overactive bladder and minimizes metabolism to N- Desethyloxy butynin compared with extended-release oral administration.

Pharmacokinetics and Metabolism of Transdermal Oxybutynin: In Vitro and in Vivo Performance of a Novel Delivery System

TLDR
Sustained delivery over 4 days and multiple sites allow a convenient, well-tolerated, twice-weekly OXY TDS dosing and the consistent delivery, absorption, and pharmacokinetics should result in an effective treatment of patients with overactive bladder.

In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.

TLDR
It is suggested that [3H]tamsulosin is a useful radioligand for in vivo measurement of alpha1 adrenoceptors in rat tissues and binds to alpha1A subtype with higher affinity than alpha1B subtype in vivo.